======= ASXL2 =======
== Gene Information ==
* **Official Symbol**: ASXL2
* **Official Name**: ASXL transcriptional regulator 2
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=55252|55252]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q76L83|Q76L83]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=ASXL2&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20ASXL2|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/612991|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene encodes a member of a family of epigenetic regulators that bind various histone-modifying enzymes and are involved in the assembly of transcription factors at specific genomic loci. Naturally occurring mutations in this gene are associated with cancer in several tissue types (breast, bladder, pancreas, ovary, prostate, and blood). This gene plays an important role in neurodevelopment, cardiac function, adipogenesis, and osteoclastogenesis. [provided by RefSeq, Feb 2017].
* **UniProt Summary**: Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. PcG proteins are not required to initiate repression, but to maintain it during later stages of development. They probably act via methylation of histones, rendering chromatin heritably changed in its expressibility (By similarity). Involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as peroxisome proliferator-activated receptor gamma (PPARG). Acts as coactivator for PPARG and enhances its adipocyte differentiation-inducing activity; the function seems to involve differential recruitment of acetylated and methylated histone H3. {ECO:0000250, ECO:0000269|PubMed:21047783}.
No Pfam Domain information is available for this gene.
|PR-DUB complex|
|positive regulation of peroxisome proliferator activated receptor signaling pathway|
|peroxisome proliferator activated receptor binding|
|regulation of peroxisome proliferator activated receptor signaling pathway|
|positive regulation of fat cell differentiation|
|regulation of fat cell differentiation|
|nuclear chromatin|
|protein deubiquitination|
|protein modification by small protein removal|
|chromatin binding|
|transcription, DNA-templated|
|nucleic acid-templated transcription|
|RNA biosynthetic process|
|animal organ morphogenesis|
|positive regulation of cell differentiation|
|protein modification by small protein conjugation or removal|
|nucleobase-containing compound biosynthetic process|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|positive regulation of transcription by RNA polymerase II|
|proteolysis|
|organic cyclic compound biosynthetic process|
|positive regulation of developmental process|
|DNA binding|
|positive regulation of transcription, DNA-templated|
|cellular nitrogen compound biosynthetic process|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|positive regulation of signal transduction|
|RNA metabolic process|
|cellular macromolecule biosynthetic process|
|positive regulation of RNA metabolic process|
|macromolecule biosynthetic process|
|regulation of cell differentiation|
|positive regulation of cell communication|
|positive regulation of signaling|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp316|Geldanamycin 0.015 to 0.025μM on day4 R07 exp316]]|-3.09|
|[[:results:exp391|Pomalidomide 20μM R07 exp391]]|-2.49|
|[[:results:exp317|Geldanamycin 0.015 to 0.05μM on day4 R07 exp317]]|-2.15|
|[[:results:exp330|5-Azacytidine 2μM R07 exp330]]|-2.06|
|[[:results:exp409|THZ531 0.11μM R07 exp409]]|-2.03|
|[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|-1.98|
|[[:results:exp438|NN-Diethyl-meta-toluamide 500μM R08 exp438]]|-1.93|
|[[:results:exp159|Docetaxel 0.001 to 0.002μM on day4 R04 exp159]]|-1.87|
|[[:results:exp505|ML-792 0.2μM R08 exp505]]|-1.85|
|[[:results:exp191|Hypoxia 5%O2 R04 exp191]]|-1.76|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|-1.76|
|[[:results:exp318|ABT-702 5μM R07 exp318]]|-1.75|
|[[:results:exp399|Salubrinal 20μM R07 exp399]]|-1.73|
|[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|-1.72|
|[[:results:exp418|Tunicamycin 0.04μM R07 exp418]]|-1.7|
|[[:results:exp34|Rotenone 20μM R00 exp34]]|1.74|
|[[:results:exp151|SGC0946 7μM R03 exp151]]|1.78|
|[[:results:exp521|Salinomycin 3.5μM R08 exp521]]|1.83|
|[[:results:exp126|GSK461364A 0.1μM R03 exp126]]|2.06|
|[[:results:exp451|Atovaquone 15μM R08 exp451]]|2.07|
|[[:results:exp59|UMK57 1μM R01 exp59]]|2.09|
|[[:results:exp67|BVD-523 15μM R02 exp67]]|2.12|
|[[:results:exp468|CB-5083 0.4μM R08 exp468]]|2.14|
|[[:results:exp217|Mdivi-1 15μM R05 exp217]]|2.19|
|[[:results:exp472|CI-1040 9.5μM R08 exp472]]|2.2|
|[[:results:exp103|Taxol 0.004μM R03 exp103]]|2.23|
|[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|2.5|
|[[:results:exp460|BML-284 0.09μM R08 exp460]]|2.57|
|[[:results:exp135|MS023 7μM R03 exp135]]|2.59|
|[[:results:exp147|Resveratrol 16μM R03 exp147]]|2.66|
^Gene^Correlation^
|[[:human genes:n:nsd1|NSD1]]|0.603|
|[[:human genes:b:bap1|BAP1]]|0.59|
|[[:human genes:i:id3|ID3]]|0.563|
|[[:human genes:i:irf2bp2|IRF2BP2]]|0.495|
|[[:human genes:d:dohh|DOHH]]|0.49|
|[[:human genes:z:zmym2|ZMYM2]]|0.481|
|[[:human genes:m:mef2c|MEF2C]]|0.469|
|[[:human genes:s:ssbp2|SSBP2]]|0.468|
|[[:human genes:h:hccs|HCCS]]|0.462|
|[[:human genes:z:zfx|ZFX]]|0.448|
|[[:human genes:r:rptor|RPTOR]]|0.443|
|[[:human genes:c:ccdc101|CCDC101]]|0.441|
|[[:human genes:m:maml1|MAML1]]|0.441|
|[[:human genes:i:irf2bp1|IRF2BP1]]|0.439|
|[[:human genes:f:fbxo11|FBXO11]]|0.434|
|[[:human genes:m:mlst8|MLST8]]|0.433|
|[[:human genes:r:rnmt|RNMT]]|0.429|
|[[:human genes:x:xpo6|XPO6]]|0.426|
|[[:human genes:t:trim28|TRIM28]]|0.424|
|[[:human genes:o:otud5|OTUD5]]|0.424|
|[[:human genes:c:cbx3|CBX3]]|0.424|
|[[:human genes:s:scaf8|SCAF8]]|0.423|
|[[:human genes:t:thg1l|THG1L]]|0.421|
|[[:human genes:d:ddx5|DDX5]]|0.419|
|[[:human genes:t:triap1|TRIAP1]]|0.419|
|[[:human genes:t:trmt10a|TRMT10A]]|0.417|
|[[:human genes:b:bptf|BPTF]]|0.416|
|[[:human genes:a:asb7|ASB7]]|0.415|
|[[:human genes:c:cbfb|CBFB]]|0.409|
|[[:human genes:s:sox7|SOX7]]|0.402|
|[[:human genes:t:trim33|TRIM33]]|0.4|
|[[:human genes:c:ctdspl2|CTDSPL2]]|0.4|
Global Fraction of Cell Lines Where Essential: N/A
^Tissue^Fraction Of Cell Lines Where Essential^
== Essentiality in NALM6 ==
* **Essentiality Rank**: 5421
* **Expression level (log2 read counts)**: 6.99
{{:chemogenomics:nalm6 dist.png?nolink |}}